Forest plots for review question 1.2 For adults with depression, what are the relative benefits and harms associated with different settings for the delivery of care?

Comparison 1. Primary care versus secondary care

Primary care versus secondary care subgroup analysis for Comparison 1a Cognitive and cognitive behavioural therapies individual + antidepressant versus antidepressant

Critical outcomes

Figure 51: Depression symptomatology at endpoint



Primary care versus secondary care subgroup analysis for Comparison 1b. Selective serotonin reuptake inhibitors (SSRIs) versus placebo

Critical Outcomes

Figure 52: Depression symptomatology at endpoint



Figure 53: Depression symptomatology change score



Figure 54: Response



Primary care versus secondary care subgroup analysis for Comparison 1c. SSRIs versus Tricyclic Antidepressants (TCAs)

Critical outcomes

Figure 55: Depression symptomatology at endpoint



Figure 56: Depression symptomatology change score



Figure 57: Remission



Figure 58: Response



Primary care versus secondary care subgroup analysis for Comparison 1d. TCAs versus placebo

Critical outcomes

Figure 59: Depression symptomatology at endpoint



Figure 60: Depression symptomatology change score



Figure 61: Response



Primary care versus secondary care subgroup analysis for Comparison 1e. Serotonin–norepinephrine reuptake inhibitors (SNRIs) versus SSRIs

Critical outcomes

Figure 62: Remission



Figure 63: Response



Comparison 2. Crisis resolution team care versus standard care (for adults with non-psychotic severe mental illness)

Critical outcomes

Figure 64: Mental health symptomatology: Symptom severity (BPRS) 8 weeks after crisis



Important outcomes

Figure 65: Service utilisation: Admission as inpatient 6 months after crisis



Figure 66: Service utilisation: Bed days in hospital 6 months after crisis



Figure 67: Psychological functioning: Quality of life (MANSA) 8 weeks after crisis



Figure 68: Social functioning: Social functioning (LSP) 8 weeks after crisis



Figure 69: Social functioning: Social functioning (LSP) 6 months after crisis



Figure 70: Satisfaction: Patient satisfaction (CSQ-8) 8 weeks after crisis



Comparison 3. Inpatient versus outpatient settings

Inpatient versus outpatient settings subgroup analysis for Comparison 3a. Selective serotonin reuptake inhibitors (SSRIs) versus placebo

Critical outcomes

Figure 71: Depression symptomatology change score

Study or Subgroup	Experimental Mean	Experimental SD	Experimental Total	Control Mean	Control SD	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
76.1.1 Inpatient								
29060 07 001	-13.08	10.2191	12	-10.91	9.386048	11	0.5%	-0.21 [-1.03, 0.61]
Sheehan 2009b	-11.42	6.46107963	99	-11.02	6.86603233	95	2.2%	-0.06 [-0.34, 0.22]
Subtotal (95% CI)			**111**			**106**	**2.6%**	**-0.08 [-0.34, 0.19]**
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.73); I² = 0%								
Test for overall effect: Z = 0.56 (P = 0.58)								
76.1.2 Outpatient								
Baune 2018	-15.96	8.58	52	-8	8.38	48	1.4%	-0.93 [-1.34, -0.52]
Binnemann 2008	-13.42	7.61	30	-10.18	7.57	31	1.0%	-0.42 [-0.93, 0.09]
Bjerkenstedt 2005	-8.9	8	54	-9.7	7	55	1.6%	0.11 [-0.27, 0.48]
Blumenthal 2007/Hoffman 2011	-6.1	6.7	49	-6.1	7.3	49	1.5%	0.00 [-0.40, 0.40]
Bose 2008	-12.1	10.22	129	-10.6	10.42	134	2.5%	-0.14 [-0.39, 0.10]
Burke 2002	-12.9	9.25	366	-9.4	9.82	119	2.7%	-0.37 [-0.58, -0.16]
Claghorn 1992a	-10.72	9.39	32	-4.59	9.35	27	1.0%	-0.65 [-1.17, -0.12]
Claghorn 1992b	-11.44	8.32	32	-5.49	8.31	27	1.0%	-0.71 [-1.23, -0.18]
Clayton 2006_study 1	-14.2	8.07	133	-12.1	7.98	130	2.5%	-0.26 [-0.50, -0.02]
Clayton 2006_study 2	-12.9	8.07	133	-11.9	7.86	126	2.4%	-0.13 [-0.37, 0.12]
Detke 2004	-11.7	4.61	85	-8.8	4.82	93	2.0%	-0.61 [-0.91, -0.31]
Dube 2010	-15	8.82	54	-13	8.84	122	1.9%	-0.23 [-0.55, 0.10]
Eli Lilly HMAT-A	-7.4	6.44	87	-4.78	6.42	89	2.0%	-0.41 [-0.70, -0.11]
Emsley 2018	-13.6	4.70319041	98	-9.5	4.82804308	106	2.1%	-0.86 [-1.14, -0.57]
Fabre 1992	-9.13	8.14	38	-3.06	8.1	36	1.2%	-0.74 [-1.21, -0.27]
Fava 1998a	-10.95	9.41	109	-11.6	8.9	19	1.1%	0.07 [-0.42, 0.56]
Fava 2005	-6.3	5.38098504	47	-7.3	4.6400431	43	1.4%	0.20 [-0.22, 0.61]
FDA 245 (EMD 68 843-010)	-11.1	7.67	92	-10.2	7.96	99	2.1%	-0.11 [-0.40, 0.17]
Forest Laboratories 2000	-12.95	9.89	243	-11.2	10.35	125	2.7%	-0.17 [-0.39, 0.04]
Forest Research Institute 2005	-16.26	10.37	266	-12.4	10.34	132	2.7%	-0.37 [-0.58, -0.16]
Golden 2002_448	-11.89	8.19	206	-9.9	8.04	101	2.5%	-0.24 [-0.48, -0.00]
Golden 2002_449	-12.69	8.2	218	-10.2	8.18	110	2.6%	-0.30 [-0.53, -0.07]
Hunter 2011	-9.67	5.78727915	12	-8.64	5.99548163	11	0.5%	-0.17 [-0.99, 0.65]
Jefferson 2000	-14.7	10.56	296	-12.1	11.05	101	2.6%	-0.24 [-0.47, -0.02]
Keller 2006_Study 062	-17.25	8.05	161	-14	8.87	154	2.6%	-0.38 [-0.61, -0.16]
Komulainen 2018	-1.9	3.05569959	17	-2.2	3.29146624	15	0.6%	0.09 [-0.60, 0.79]
Kranzler 2006_Group A	-10.8	6.5	89	-9.6	7.8	100	2.1%	-0.17 [-0.45, 0.12]
Lam 2016	-8.8	9.9	31	-6.5	9.6	30	1.1%	-0.23 [-0.74, 0.27]
Macias-Cortes 2015	-8.9	2.45051015	46	-5.7	2.46880538	43	1.2%	-1.29 [-1.75, -0.83]
Mathews 2015	-15.9	10.04	280	-13.6	10.06	281	3.1%	-0.23 [-0.39, -0.06]
Miller 1989a	-6	5.9	19	-6.2	7.2	22	0.8%	0.03 [-0.58, 0.64]
Mundt 2012	-13.4	5.7	55	-10.7	6.6	50	1.5%	-0.44 [-0.82, -0.05]
MY-1042/BRL-029060/CPMS-251	-10.23	7.67	120	-8.25	7.56	123	2.4%	-0.26 [-0.51, -0.01]
MY-1045/BRL-029060/1 (PAR 128)	-12.39	8.77	694	-9	8.63	136	3.0%	-0.39 [-0.57, -0.20]
Nierenberg 2007	-7.22	6.62	274	-5.97	6.79	137	2.8%	-0.19 [-0.39, 0.02]
NKD20006 (NCT00048204)	-11.1	7.9	117	-10.9	7.8	118	2.4%	-0.03 [-0.28, 0.23]
PAR 01 001 (GSK & FDA)	-13.36	7.93	22	-11.33	7.93	21	0.8%	-0.25 [-0.85, 0.35]
Rapaport 2009	-12.11	8.02	173	-8.85	8	178	2.7%	-0.41 [-0.62, -0.19]
Reimherr 1990	-11.66	8.24	142	-8.16	7.85	141	2.5%	-0.43 [-0.67, -0.20]
SER 315 (FDA)	-8.9	4.52	76	-7.8	8	73	1.9%	-0.17 [-0.49, 0.15]
Stark 1985	-11	10.1	185	-8.2	9	169	2.7%	-0.29 [-0.50, -0.08]
Study 62b (FDA)	-8.82	8.71	297	-5.69	8.65	48	2.0%	-0.36 [-0.66, -0.05]
Study F1J-MC-HMAQ - Study Group B	-7.63	7	37	-7.1	6.96	72	1.5%	-0.08 [-0.47, 0.32]
Tollefson 1993/1995	-8.1	7.6	326	-6.4	7.1	329	3.2%	-0.23 [-0.38, -0.08]
VEN XR 367 (FDA)	-11.26	10.55	80	-13.1	10.63	81	2.0%	0.17 [-0.14, 0.48]
Wade 2002	-14.9	6.56658206	188	-12	6.78196137	189	2.8%	-0.43 [-0.64, -0.23]
WELL AK1A4006	-13.9	10.87	146	-12.2	9.73	148	2.6%	-0.16 [-0.39, 0.06]
Wernicke 1987	-8.83	8.67	297	-5.7	8.6	48	2.0%	-0.36 [-0.67, -0.05]
Wernicke 1988	-10.6	8.3	183	-7	8.6	77	2.3%	-0.43 [-0.70, -0.16]
Subtotal (95% CI)			**6916**			**4716**	**97.4%**	**-0.29 [-0.36, -0.23]**
Heterogeneity: Tau² = 0.02; Chi² = 105.28, df = 48 (P < 0.00001); I² = 54%								
Test for overall effect: Z = 9.46 (P < 0.00001)								
Total (95% CI)			**7027**			**4822**	**100.0%**	**-0.29 [-0.35, -0.23]**
Heterogeneity: Tau² = 0.02; Chi² = 107.84, df = 50 (P < 0.00001); I² = 54%								
Test for overall effect: Z = 9.44 (P < 0.00001)								
Test for subgroup differences: Chi² = 2.47, df = 1 (P = 0.12), I² = 59.4%								



Figure 72: Response



Inpatient versus outpatient settings subgroup analysis for Comparison 3b. SSRIs versus tricyclic antidepressants (TCAs)

Critical outcomes

Figure 73: Depression symptomatology endpoint



Figure 74: Depression symptomatology change score



Figure 75: Remission



Figure 76: Response



Inpatient versus outpatient settings subgroup analysis for Comparison 3c. Serotonin–norepinephrine reuptake inhibitors (SNRIs) versus placebo

Critical outcomes

Figure 77: Depression symptomatology endpoint



Figure 78: Depression symptomatology change score



Figure 79: Remission



Inpatient versus outpatient settings subgroup analysis for Comparison 3d. SNRIs versus SSRIs

Critical outcomes

Figure 80: Depression symptomatology endpoint



Figure 81: Depression symptomatology change score



Figure 82: Remission



Figure 83: Response



Inpatient versus outpatient settings subgroup analysis for Comparison 3e. Mirtazapine versus TCAs

Critical outcomes

Figure 84: Response



Inpatient versus outpatient settings subgroup analysis for Comparison 3f. Acupuncture + antidepressants versus antidepressants

Critical outcomes

Figure 85: Depression symptomatology change score



Comparison 4. Acute psychiatric day hospital care versus inpatient care (for adults with depression and non-psychotic severe mental illness)

Critical outcomes

Figure 86: Psychiatric symptom severity at 2-3 months post-admission



Figure 87: Psychiatric symptom severity at 12-14 months post-admission



Figure 88: Remission (HAM-D<7/Present State Examination: Index of Definition ≤4)



Figure 89: Response (at least 47% improvement on HAM-D)



Important outcomes

Figure 90: Duration of index admission



Figure 91: Readmission



Figure 92: Service utilisation: Emergency contacts



Figure 93: Service utilisation: Outpatient contact



Figure 94: Quality of life (MANSA)



Figure 95: Social functioning impairment (GSDS-II)



Figure 96: Social functioning response



Figure 97: Satisfaction (number of participants satisfied or very satisfied with their treatment)



Figure 98: Satisfaction (CAT)



Figure 99: Carer distress (GHQ change score)



Comparison 5. Non-acute day hospital care versus outpatient care (for adults with depression and non-psychotic severe mental illness)

Critical outcomes

Figure 100: Psychiatric symptom severity (Psychiatric Evaluation Form/Present State Examination; change score)



Important outcomes

Figure 101: Service utilisation – admission as inpatient



Figure 102: Social functioning (SAS-SR/SFS; change score)



Figure 103: Global functioning (GAS; change score)



Figure 104: Satisfaction (number of participants satisfied or very satisfied with their treatment)



Comparison 6. Community mental health teams versus standard care (for adults with non-psychotic severe mental illness)

Critical outcomes

Figure 105: Psychiatric symptom severity (CPRS at endpoint)



Important outcomes

Figure 106: Service utilisation – admission as inpatient



Figure 107: Service utilisation – admission as inpatient for >10 days



Figure 108: Satisfaction – number of participants satisfied with their treatment



Figure 109: Satisfaction – service satisfaction score